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A randomized multicenter clinical trial comparing isosmolar
Icodextrin with hyperosmolar glucose solutions in CAPD
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England, United Kingdom
A randomized multicenter clinical trial comparing isosmolar Icodex-
trin with hyperosmolar glucose solutions in CAPD. The osmotic effec-
tiveness of a large molecular weight glucose polymer fraction (Icodextrin)
as a novel "colloid" osmotic agent in peritoneal dialysis was established,
but the long-term safety remained undetermined. A randomized, con-
trolled multicenter investigation of Icodextrin in ambulatory peritoneal
dialysis (MIDAS) was undertaken to evaluate the long-term safety and
efficacy by comparing daily overnight (8 to 12 hr dwell) use of isosmolar
Icodextrin (282 mOsmlkg) with conventional 1.36% (346 mOsmlkg) and
3.86% (484 mOsmlkg) glucose exchanges over six months. Two hundred
and nine patients were randomized from 11 centers, with 106 allocated to
receive Icodextrin (D) and 103 to remain on glucose (control group; C);
138 patients completed the six month study (71 C, 67 D). All patients were
divided into weak (1.36%) or strong (3.86%) subgroups based on their use
of glucose solutions overnight during the pretreatment baseline period.
The mean (± SEM) overnight ultrafiltration (UF) with D was 3.5 times
greater than 1.36% glucose at eight hours [527 36 vs. 150 47 ml; 95%
confidence interval (CI) for the difference +257 to +497 ml; P < 0.0001]
and 5.5 times greater at 12 hours (561 44 vs. 101 48 ml, 95% CI for
the difference +329 to +590; P < 0.0001) and no different from that of
3.86% glucose at eight hours (510 48 vs. 448 60 ml, 95% CI for the
difference —102 to +226 ml; P = 0.44) and at 12 hours (552 44 vs. 414
78 ml, 95% CI for the difference —47 to +325 ml; P = 0.06). The
biochemical profiles were no different in the two groups except for a small
fall in serum sodium (140 to 136 mmol/liter) and chloride (103 to 99
mmol/liter) concentrations in the Icodextrin group. The mean serum
maltose increased from a pre-dialysis value of 0.04 g/liter to a steady state
level of 1.20 g/liter within two weeks and remained stable throughout the
study. This was not associated with any adverse clinical effects and the
overall CAPD-related symptom score was significantly better for D than
C. This study demonstrates that the daily overnight use of an isosmolar
Icodextrin solution was safe and effective up to six months and could
replace the overnight use of hyperosmolar glucose solutions. Longer term
data will be necessary to establish further safety and efficacy.
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Continuous ambulatory peritoneal dialysis (CAPD) has become
established as an alternative to hemodialysis and is utilized in
about half the dialysis population in the United Kingdom [11.
Currently, glucose is the only osmotic agent in use but it is
associated with several long-term complications. These are pri-
marily related to rapid absorption through the peritoneum result-
ing in ultrafiltration of short duration and metabolic complica-
tions such as hyperglycemia, hyperinsulinemia, hyperlipidemia
and obesity [2]. In addition, there has been growing concern that
the hyperosmolality and low pH of this solution may damage the
peritoneum and, thereby threaten its viability as a dialyzing
membrane [3, 4]. Thus, the need for a more physiological solution
containing an osmotic agent that would provide sustained ultra-
filtration and minimize the metabolic complications has led to an
extensive but hitherto unsuccessful search for alternatives [5].
More recently, using a large molecular weight glucose polymer
fraction derived from hydrolyzed corn starch, we have successfully
adapted the physiological phenomenon of colloid osmosis to
generate ultrafiltration in peritoneal dialysis [6]. An isosmolar
solution of glucose polymer produces sustained ultrafiltration for
up to 12 hours with lower transperitoneal absorption and poten-
tial calorie load compared to glucose solutions. Furthermore, the
lack of hyperglycemia and hyperinsulinemia associated with its
use may offer some long-term metabolic advantages and possibly
simplify management of diabetic patients [7].
Although only a fraction of glucose polymer load is absorbed,
its metabolism is nevertheless incomplete. The absorbed polymer
is rapidly hydrolyzed by amylase to oligosaccharidcs and eventu-
ally to the disaccharide, maltose; further metabolism is limited by
the absence of maltase activity in the human circulation [8, 9].
Even though substantial amounts of maltase activity have been
demonstrated in a variety of extraintestinal tissues [10, 111,
including the kidneys [12, 131, maltose accumulation is known to
occur in renal failure [6]. In a short-term study, using a single
overnight exchange, a 36-fold increase in maltose level in CAPD
patients was not associated with any adverse effects [6, 14].
However, the long-term consequences remained unknown and
cause for concern.
So far the experience with glucose polymer has been confined
to a small number of patients in a single center [6, 14]. The
present study (Multicentre Investigation of Icodextrin in Ambu-
latory Peritoneal Dialysis—MIDAS) was therefore designed to
investigate the long-term safety and efficacy in a larger, more
heterogeneous, group of patients representative of the CAPD
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population in the United Kingdom (UK). Since the isosmolar
glucose polymer (termed Icodextrin hereafter) solution was highly
effective over long dwell exchanges, a single daily overnight use of
Icodextrin with daytime exchanges of conventional glucose
seemed most appropriate. This randomized controlled trial com-
pared Icodextrin with glucose solutions during the overnight dwell
of 8 to 12 hours over six months, in CAPD patients from 11 renal
units in the UK. The trial was conducted over the period of March
1991 to February 1992.
Methods
Patients
Patients were eligible for the study if they were aged 18 years or
over and established on CAPD for at least three months using
standard three to four exchanges, with no more than one "strong"
hypertonic glucose bag (3.86% glucose) per 24 hours. The patients
were also free of peritonitis and mechanical drainage complica-
tions for at least one month prior to the study.
Approval was obtained from local ethical committees at each
center and written informed consent given by every patient.
Randomization and treatment
Patients were randomized into Icodextrin (D) or control glu-
cose (C) groups by telephone from a single office (Innovata
Biomed) at the first visit. Patients in the Icodextrin group used a
1.5 or 2 liter dialysis bag containing 7.5% Icodextrin, in place of
their usual bag of glucose solution for the overnight dwell, while
the control group continued their usual CAPD exchanges. The
dialysis regimen remained unchanged except for three special
study weeks when all patients underwent 12-hour overnight
dwells. These were weeks 4, 13, and 21. The patients were allowed
to change the concentration or the number of daytime glucose
exchanges to maintain adequate fluid balance. All changes were
recorded.
Patients continued with their usual medication and no specific
alterations to diabetic treatment were recommended other than
the usual stringent care of diabetic control. All changes during the
study were recorded. Patients could withdraw permanently at any
time, and were allowed up to four weeks temporary withdrawal
(holidays abroad, intra-abdominal complications). Peritonitis per
se was not a reason for withdrawal.
Monitoring
In each center, a Nurse Monitor was employed to co-ordinate
the study. The study treatment began at visit 2; patients were seen
every other week for the first two months and every four weeks for
the remaining time on the study. Body weight, blood pressure and
changes in medication were recorded at each visit. Patients kept a
diary throughout the study and recorded the weights of bags
before and after each overnight dwell, as well as the duration of
exchanges. For the three special weeks, bag weights were recorded
for all exchanges.
Blood samples for hematology, standard biochemistry (includ-
ing osmolality) were collected at each visit; serum samples for
estimation of Icodextrin and oligosaccharides were obtained
immediately prior to the study and at one, three and six months.
Fasting lipids, residual creatinine clearance, CXR, ECG and
ophthalmological assessment (visual acuity, slit lamp examination,
fundoscopy) were made on each patient before and after six
months of treatment.
Patients were asked to report all medical events which occurred
during the study. These were elicited by open questioning. In
addition, a list of 12 common symptoms in CAPD patients (pain
during exchange, abdominal fullness, night cramps, loss of appe-
tite, constipation, diarrhea, thirst, difficulty maintaining correct
weight, shortness of breath, ankle swelling, tiredness and visual
disturbance) were graded on a scale 0 to 3 (0 = none, 1 = mild,
2 = moderate and 3 severe) at each visit during the study, and a
composite score determined for each patient.
Composition of dialysate
Icodextrin was manufactured by M.L. Laboratories plc., and
dialysis solution constituted by Baxter and Fresenius in a manner
identical to conventional glucose solutions. The composition of
Icodextrin solution (mmol/liter) was: sodium 133, chloride 97,
lactate 40, calcium 1.75, magnesium 0.25, Icodextrin 12.5. The
Icodextrin contained glucose polymer chain length varying be-
tween 4 to 250 glucose units with weight average molecular weight
(Mw) of 16,200 and number average molecular weight (Mn) of
5,800. The total osmolality of 7.5% Icodextrin solution was 282
mOsmlkg and the pH 5.3.
The osmolalities of commercially available glucose solutions
supplied by Baxter/Fresenius were 346 mOsmlkg for 1.36%/1.5%
and 484 mOsmlkg for 3.86%14.25%; pH 5.2.
Statistical analysis
The primary efficacy analysis of overnight ultrafiltration volume
and CAPD symptomatology was on an intent-to-treat basis using
the last values carried forward, thereby including all data available
from withdrawn patients. Secondary analyses, excluding patients
who violated the entry criteria (9 C, 4 D) and excluding those who
also had variable bag regimens during the study (39 C, 45 D) were
undertaken, but are not presented here as the results were
qualitatively identical to the primary analysis.
The main parameter for efficacy was the volume produced after
the overnight dwell at 12 hours (special weeks 4, 13 and 21) and
at 8 hours (weeks 3, 12 and 20). The median value over the week
was taken for each patient to avoid undue influence of outlying
values (weeks with 3 values or fewer were excluded, and the
equivalent "last value" used), and the mean of the medians in
each group were compared by repeated measures analysis of
variance. Patients were subdivided into a "weak bag group" or a
"strong bag group" according to whether they used 1.36% or
3.86% glucose solutions for the overnight dwell, respectively,
during the baseline period (between randomization and the start
of treatment).
For safety, adverse events, clinical and laboratory measure-
ments, all available data were included in the analyses.
All tests were two-sided and conducted at the 5% level of
significance. Significance levels for laboratory data were adjusted
for multiple testing by a modified method of Bonferroni [15].
Results
Of the 209 patients randomized from the 11 centers, 106 were
allocated to Icodextrin (D) and 103 to glucose (C). Of the total, 26
were diabetic (11 C, 15 D). The patients in the C and D groups
were well matched for age, sex, primary renal disease, duration of
dialysis and medical complications. The peritonitis rate prior to
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Table 1. Patient characteristics
Control Icodextrin
No. patients randomized 103 106
Males 67 71
Females 36 35
Age years
Mean SD 55 15 55 14
Range 22—82 18—77
Weight kg (Mean SD) 70.5 14.2 71.4 13.4
CAPD profile
Duration of CAPD therapy months 27.6 25.6 24.7 19.8
(mean sn)
Exchange vol
2.0 liters 91 89
1.5 liters 12 17
Overnight hypertonic exchanges (No. 32 31
patients)
Episodes of peritonitis/patient months 1:21 1:15
Residual renal function C. > 2 mi/mm 37 38
Medical history (No. patients)
Obstructive airways disease 8 10
Hypertension 35 45
Coronary heart disease 14 20
Peripheral vascular disease 2 5
Primary renal disease
Glomerulonephritis 16 17
Polycystic kidney disease 10 10
Hypertension 24 24
Chronic pyelonephritis 10 11
Diabetes mellitus 8 11
Heredofamilial diseases 2 0
Unknown 33 33
the study was, however, 1.4 times higher in the D group (Table 1).
Sixty-seven percent of the CAPD population studied used at least
one 3.86% glucose ("strong") exchange per 24 hours. The overall
and overnight usage of strong glucose was similar in the two
groups.
Of the C group, there were 54 and 35 in the weak and strong
subgroups, respectively, while in the D group there were 46 and
30. A few patients had no consistent pattern of weak or strong bag
use (4 C, 9 D) or had not completed diaries (6 C, 11 D) or
withdrew during the baseline period (4 C, 10 D), were not
allocated to either of these subgroups.
A total of 71 patients withdrew during the study, of whom 14 (4
C, 10 D) did so between randomization and starting treatment; 57
(28 C, 29 D) withdrew during treatment. The most common
reasons for withdrawal were transplantation and cardiovascular
events (Table 2). When major and minor adverse events were
assessed for relationship to Icodextrin treatment, no specific
association was observed except in one patient with cardiac failure
in whom Icodextrin mediated ultrafiltration was lower than 3.86%
glucose and may have contributed to fluid overload.
One hundred and thirty-eight patients (71 C, 67 D) completed
the six month study (66% of randomized; 72% of those who
started treatment).
Efficacy
Ultrafiltration, The mean (± SEM) overnight ultrafiltration (UF)
with D was 3.5 times greater than 1.36% glucose (G) at eight
hours [527 36 vs. 150 47 ml; 95% confidence interval (CI) for
the difference +257 to +497 ml; P < 0.0001] and 5.5 times greater
at 12 hours (561 44 vs. 101 48 ml, 95% CI for the difference
Table 2. Number of patients withdrawn before and during treatment
Control Icodextrin
Before During Before During Total
Loss of ultrafiltration
Cather related problems
Adverse events (e.g.
peritonitis)
Withdrawals > 4 weeks
Patient request
Non-compliance
Transplant
Transfer to hemodialysis
Other
1
0
0
0
1
0
0
0
2
1
1
6
5
2
2
7
2
2
2
1
1
0
2
0
3
0
1
3
3
8
3
4
1
6
1
0
7
5
15
8
9
3
16
3
5
Total 4 28 10 29 71
32 39
+329 to +590; P < 0.0001) and no different from that of 3.86%
G at eight hours (510 48 vs. 448 60 ml, 95% CI for the
difference —102 to +226 ml; P = 0.44) and at 12 hours (552 44
vs. 414 78 ml, 95% CI for the difference —47 to +325 ml; P =
0.06). The numbers of patients in each of these groups are shown
in Figure 1. Extending the dwell time from 8 to 12 hours tended
to reduce net UF with glucose but to increase it with Icodextrin
(Fig. 1). In contrast to Icodextrin, 9 to 41% of patients on glucose
experienced net overnight reabsorption of intraperitoneal fluid
(negative UF; Fig. 2). The mean UF per week was relatively
constant in both groups but between-patient variability was higher
in the C compared to the D group throughout the study.
The overnight use of Icodextrin did not influence the daytime
UF with glucose solutions: in weeks 4, 13 and 21 the daytime UF
volumes were (mean SEM) 352 46, 331 51 and 331 51,
respectively, in the C group and 331 55, 361 62 and 311 66,
respectively, in the D group (NS). The daytime use of 3.86%
glucose exchanges was lower in the D patients compared to the C
in the weak bag group (1.2 0.3 vs. 2.4 0.3 bags/wk), but the
situation was reversed in the strong bag group (2.7 0.31 vs. 1.9
0.3 bags/wk), despite similar overnight UF with Icodextrin.
Solute transport. The transperitoneal transport as assessed by
serial measurement of solute plasma concentration shows that
small molecular weight solutes such as potassium, urea, creati-
nine, calcium, phosphate, uric acid, as well as large Mw solutes,
such as albumin and total protein, were similar in the two groups
but a small, statistically significant fall in serum sodium and
chloride levels was observed irs the D group compared to the C
(Table 3).
Lipids. Lipid profiles were similar in both groups at entry. In the
Dextrin group, however, the cholesterol, triglycerides and LDL
levels fell by 6 to 10% of the pretreatment values, but these
changes did not achieve statistical significance.
Safety
Icodextrin absoiption and serum levels. The total carbohydrate
absorbed from the eight hour overnight exchanges was deter-
mined in 18 (7 C, 11 D) patients, by subtracting the amount of
carbohydrate in the dialysate at the end of the dwell from that
infused. All control patients used strong bags overnight. During
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Fig. 1. Net overnight ultrafiltration with glucose
and Icodextrin exchanges. The volume is
expressed as the mean of the medians in each
group with last values carried forward. Symbols
are: (LI) 1.36% glucose; () Icodextrin; (11)
3.86% glucose. Error bars = SEM; < 0.001.
Numbers within bars represent patients in each
Week group.
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glucose exchanges 86% of the initially infused carbohydrate was
absorbed compared with 20% of Icodextrin. The mean (± SEM)
carbohydrate absorption was lower with Icodextrin (29 5 g)
than with 3.86% glucose (62 5g; P < 0.01).
B l2hrdwell
3 12 20
Week
I'
4 13 21
Week
[] L'.1 J Fig. 2. Percentage of patients with negative
ultrafiltration during overnight dwell. Numbers of4 13 21 patients are as in Fig. 1. Symbols are: (LI)
1.36% glucose; () Icodextrin; () 3.86%
Week glucose.
Figure 3 shows circulating levels of the total Icodextrin fractions
(maltose two high molecular weight fractions; G2-HMW) and mal-
tose (G2) alone over a period of six months. The mean level of
Icodextrin and its metabolites (total Icodextrin) increased from a
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Table 3. Biochemical profile during glucose (C) and Icodextrin (D) exchanges (mean SEM)
Solute Pre Week 2 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 p
Weight kg C
D
70.5 1.4
71.4 1.4
71.0 1.5
70.9 1.5
70.8 1.5
71.0 1.5
71.0 1.6
70.7 1.6
71.0 1.7
71.0 1.6
71.1 1.7
70.5 1.7
71.6 1.8
70.3 1.7
71.4 1.9
70.1 1.6 NS
Hbg/dl C
D
9.8±0.2
10.1 0.2
9.6±0.2
9.9 0.2
9.7±0.2
9.8 0.2
9.7±0.2
9.9 0.2
9.7±0.2
9.9 0.2
9.8±0.2
10.2 0.2
9.9±0.2
10.3 0.3
9.9±0.2
10.4 0.2 NS
Sodium C 139 0.3 139 0.4 139 0.4 139 0.4 138 0.4 139 0.4 138 0.4 138 0.4
mmol/liter D 140 0.3 137 0.4 136 0.3 137 0.3 136 0.3 136 0.3 136 0.3 136 0.3 <0.05
Chloride C 103 0.5 102 0.5 103 0.5 103 0.6 103 0.6 103 0.7 102 0.7 103 0.7
mmol/liter D 103 0.7 99 0.7 99 0.7 100 0.7 100 0.5 99 0.6 98 0.7 99 0.6 <0.05
Urea C 22.9 0.5 23.3 0.5 22.9 0.5 23.2 0,6 22.8 0.6 23.0 0.6 22.8 0.6 22.9 0.6
mmol!liter D 22.0 0.6 21.8 0.6 22.4 0.7 21.4 0.6 21.7 0.6 21.9 0.7 22.5 0.6 22.5 0.7 NS
Cr pmol/liter C
D
1008 23
974 27
1013 24
943 31
1018 25
961 32
1023 26
931 28
1031 27
935 28
1034 27
950 30
1044 27
966 31
1052 30
974 32 NS
Phosphate C 1.75 0.05 1.70 0.04 1.75 0.05 1.72 0.04 1.75 0.05 1.75 0.05 1.72 0.05 1.80 0.05
mmol/liter D 1.71 0.04 1.65 0.04 1.69 0.05 1.63 0.05 1.63 0.05 1.62 0.05 1.62 0.04 1.66 0.04 NS
Albumin C 36 0.5 35 0.5 36 0.5 36 0.5 360 0.5 36 0.5 35 0.5 36 0.5
giliter D 36 0.4 35 0.4 35 0.4 35 0.4 35 0.5 36 0.4 35 0.5 36 0.5 NS
Plasma osmolality C 310 1.1 310 1.0 309 1.0 309 1.2 308 1.1 310 1.1 310 1.2 311 1.4
mOsm/kg D 310 1.0 311 1.1 312 1.4 311 1.1 311 1.1 313 1.2 313 1.1 313 1.3 NS
baseline value of 0.35 0.02 g/liter to a steady state level of 4.87
0.17 glliter and remained stable throughout the study. The
serum maltose followed an identical pattern and rose from 0.04
0.004 glliter to a steady state level of 1.20 0.043 g/liter.
Osmolality. The use of Icodextrin solution resulted in a slight
rise in serum osmolality compared to the control group but this
change was not statistically significant (Table 3).
Liver ,funcsion tests. Liver function tests performed during the
study remained normal in both groups.
Medical profile and symptomatology. Most patients tolerated
their treatment well. Major adverse events were similar in the two
groups, and were mainly related to pre-existing cardiovascular
disease (Table 4). Two deaths occurred during the study, both in
the C group; one patient died in the D group a week after
withdrawal from the study, due to cerebrovascular accident
(CVA). The numbers of patients receiving erythropoietin therapy
were similar in the two groups (24 C, 25 D).
There was a significant (P < 0.05) reduction in the overall
CAPD-related symptom score at the end of the six month study
period in the D group compared to the C (Figure 4). The
symptomatic improvement was particularly noted in abdominal
fullness, tiredness, shortness of breath and effective maintenance
Control Icodextrin
Myocardial infarction 4 2
Cardiac failure 1 1
Cardiovascular accident 2
Pneumonia — 1
Uncontrolled hypertension — 1
Pulmonary embolus — 1
Multiple arterial emboli 1 —
Peritonitis episodes/patient
month
Pre-MIDAS 1:21 1:15
During the study 1:16 1:13
of dry weight. The mean number of non-CAPD related medical
events (that is, all other medical events not classified as pertaining
to CAPD) in the C and the D groups were 3.1 and 2.6 per patient,
respectively. Ophthalmological assessments before and after
treatment did not show any pattern of abnormality in the D group
compared to the C.
The peritonitis rate during the study was higher in the Icodex-
trin group, consistent with the higher rate at entry, but there was
no significant difference between the two groups (Table 4).
Diabetic patients
A subgroup analysis of diabetic patients showed a similar
pattern of changes with respect to ultrafiltration, biochemistry,
polymer accumulation and symptom profile to non-diabetic pa-
tients. The overall diabetic control and insulin requirements were
not different in the two groups.
Discussion
This study, involving approximately 5% of the UK CAPD
population, was the first large long-term, randomized controlled
study undertaken to compare the efficacy and safety of a new
osmotic agent, Icodextrin, with conventional glucose solutions. It
demonstrated that the overnight use of Icodextrin, which is
isosmolar, was well tolerated and produced ultrafiltration superior
to 1.36% glucose, and no difference in the magnitude to hyper-
tonic 3.86% glucose solution was found.
Table 4. Major adverse events
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Week
Fig. 4. The overall symptom score in each group before and at the end of
study. Symbols are: (fl) 1.36% glucose; (•) Icodextrin. Error bars = SEM,
< 0.05 between groups.
As expected, the short duration of effective ultrafiltration with
glucose solutions (2 to 4 hr) resulted in net reabsorption of
intraperitoneal volume (negative ultrafiltration) during the long
overnight dwell in a substantial proportion of patients [7, 161. This
was particularly marked for 1.36% exchanges, but also occurred in
some patients using a 3.86% solution. In contrast, the sustained
ultrafiltration associated with Icodextrin solution led to negligible
reabsorption. This supports our previous view that it could
effectively replace all overnight glucose exchanges, especially
3.86% glucose where the additional benefits in terms of osmolar
and carbohydrate load are even greater [6]. Furthermore, the
ultrafiltration kinetics of Icodextrin differ from glucose in having
a lower rate of ultrafiltration at the onset of dialysis but being
sustained over a longer period [7], which may explain the reduced
sensation of abdominal fullness in the Icodextrin group.
The overall overnight ultrafiltration achieved by Icodextrin was
on average no different from 3.86% glucose solutions, but there
was a small rise in daytime use of 3.86% glucose exchanges (one
bag per week) in the patients using Icodextrin in the strong bag
group. This may be due to between-center variation in the criteria
for the use of hypertonic exchanges and restriction of fluid intake.
The reduced daytime use of 3.86% exchanges in the weak bag
group, on the other hand, is predictable on the basis of the large
improvement in overnight ultrafiltration with Icodextrin.
In this study, the long-term use of Icodextrin had no detectable
influence on peritoneal function as judged by sequential estima-
tion of ultrafiltration rates and solute transport characteristics.
However, a much smaller between-patient variation in ultrafiltra-
tion compared to the controls is of some interest. The precise
cause for this remains uncertain but it probably relates to different
pathways of transperitoneal absorption of osmotic agents. The
absorption of small Mw glucose through the peritoneal "pores" is
subject to considerable variability [17, 18], whereas macromolec-
ular absorption is relatively constant through the lymphatic system
[19—22]. In previous studies, the transperitoneal absorption of
Icodextrin has varied between 24 and 28% over 8 to 12 hours,
which is in consistent with lymphatic uptake [6, 7, 14]. A similar
finding in the subgroup of patients in this study is in accordance
with this hypothesis.
The pattern of systemic accumulation of Icodextrin and its
breakdown products represents an important component of the
safety analysis in this study. It is consistent with previous experi-
ence both in the magnitude of the rise and the time interval to
reach steady state levels for maltose and larger fractions [141.
Furthermore, steady state levels were maintained despite the
longer duration of this study. This implies that a dynamic equi-
librium is reached between the absorbed Icodextrin, degradation
products and their peritoneal/metabolic clearances. It is possible
that some extrarenal maltose metabolism occurs in uremic pa-
tients as the previously calculated small transperitoneal clearance
of maltose (3.5 ml/min) during daytime glucose exchanges alone[6, 7] may be insufficient to account for the total clearance
observed. However, in contrast to normal subjects [8, 23—25],
there are no detailed metabolic studies of maltose available in
uremic patients.
The levels of maltose and oligosaccharides over six months
represent the longest exposure of these substances in uremic
patients. During this period no adverse clinical effects were
ascribed to Icodextrin or its metabolites. Interestingly, the pa-
tients in the Icodextrin group reported an improved symptom
profile, but no firm conclusion could be drawn from this due to the
open nature of the study. However, it is relevant that at the end of
the study most patients (72%) in the group opted to continue with
the daily use of Icodextrin. The majority of them have been using
it for up to 24 months without adverse effects.
There has been concern expressed regarding possible tissue
accumulation of dextran [26—28] and hydroxyethyl starch [29], and
that this may occur with Icodextrin. However, in contrast to
polysaccharides such as dextran and hydroxyethyl starch which are
relatively undegradable, Icodextrin is a highly soluble product
consisting mainly of one to four a glucosidic bonds which are
readily metabolized by intra- and extracellular amylase and
maltase [30]. Although a lack of renal maltase leads to extracel-
lular accumulation of maltose in uremia, the enzyme is abundantly
present intracellularly within lysozymes [3 1—33]. Thus, intracellu-
larly transported maltose would be completely metabolized. In
renal failure there is no evidence of an intracellular maltase/
isomaltase defect [34, 35], and so the possibility of glycogen
storage or tissue deposition is unlikely. It has been shown that
maltose diffuses readily across some cell walls, but the relative
impermeability of the human cellular membrane represents an
important rate limiting step in the intracellular metabolism of
maltose [36]. Whether the elevated level of maltose is capable of
non-enzymatic tissue glycation is unknown and is the subject of
further study.
In contrast to poorly metabolized small molecular weight
osmotic agents [37, 38], the relative contribution of Icodextrin to
total serum osmolality is negligible due to its low absorption and
generation of maltose and isomaltose. These fractions, having
molecular sizes greater than glucose, generate a much lower
molar concentration per unit mass and thus are less likely to lead
to hyperosmolality. In the present study, the combined concen-
tration of Icodextrin and all its metabolites amounted to less than
3.5 mmol/liter, which was insufficient to affect the serum osmo-
lality significantly during the course of the study.
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However, the precise cause of hyponatremia in the Icodextrin
group remains uncertain. One possible explanation may be that
accumulation of Icodextrin and its metabolites, though insufficient
to affect total serum osmolality (isosmolar), are relatively imper-
meable across the cell membrane (with high refection coefficient)
and may induce osmotic flow by a mechanism similar to isosmolar
"colloid" osmosis. Perhaps the flow of water from intracellular to
extracellular compartment could lead to dilutional hyponatremia.
Alternatively, according to the recent "three-pore" theory of
transperitoneal fluid and solute transport proposed by Stelin and
Rippe [39], up to 50%of transperitoneal ultrafiltration induced by
glucose (radius 3 A) occurs via the transcellular pores (4 to 6 A)
not coupled to solute transport. Thus, a substantial sieving of
sodium gives rise to hyponatremic dialysate in the early phase of
glucose based dialysis. In contrast, the large molecular weight
Icodextrin (radius 20 to 30 A) probably mediates a large propor-
tion of transcapillary ultrafiltration through the small intracellular
pores (40 to 55 A) with relatively less sieving of sodium and
therefore larger dialysate loss. Nevertheless, the small reduction
in serum sodium, although statistically significant, does not appear
to be clinically relevant as no adverse effects have been attributed
to it in this study or during the subsequent long-term use of 24
months (unpublished observation).
The maltose and related fractions do not affect glucose metab-
olism nor lead to hyperinsulinemia [24,40]. It is therefore possible
that this may have a favorable impact on the lipid profile.
Although, the cholesterol levels showed some reduction during
the study, this did not reach statistical significance. It seems that
a single isosmolar exchange per day is not sufficient to produce a
detectable change, and perhaps multiple exchanges over a longer
period of observation are required. The results of the MIDAS
study in the subgroup of patients with diabetes will be the subject
of a separate report.
This large multicenter, randomized controlled study has dem-
onstrated that an isosmolar Icodextrin solution was well-tolerated
over six months and was as effective as 3.86% glucose over long
dwell exchanges. In its present form, a daily overnight use would
obviate the need for hypertonic glucose exchanges, particularly
3.86% glucose, but would be equally effective in any long dwell
regimes such as the daytime use in automated peritoneal dialysis
(APD). In addition, the safety aspect of this study marks an
important advance towards the ultimate objective of developing a
physiological solution suitable for all CAPD exchanges. Our
previous work suggested that an isosmolar combination of small
and large molecular agents is effective in producing optimal
ultrafiltration for a given dwell time [41]. For shorter daytime
exchanges (4 to 6 hr) an isosmolar combination of only a quarter
of the concentration of currently used Icodextrin and a half the
1.36% glucose may be sufficient. It would have the advantage of
replacing all the currently used hyperosmolar exchanges with
physiological solutions containing half the daily calorie load
without exceeding the current level of maltose accumulation.
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